Form 8-K - Current report:
SEC Accession No. 0001104659-26-081616
Filing Date
2026-07-08
Accepted
2026-07-08 09:01:16
Documents
14
Period of Report
2026-07-07
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2619949d1_8k.htm   iXBRL 8-K 31592
2 EXHIBIT 10.1 tm2619949d1ex10-1.htm EX-10.1 68183
3 EXHIBIT 10.2 tm2619949d1ex10-2.htm EX-10.2 73302
4 EXHIBIT 10.3 tm2619949d1ex10-3.htm EX-10.3 73118
  Complete submission text file 0001104659-26-081616.txt   465269

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA gpcr-20260707.xsd EX-101.SCH 3023
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE gpcr-20260707_lab.xml EX-101.LAB 34239
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gpcr-20260707_pre.xml EX-101.PRE 22364
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2619949d1_8k_htm.xml XML 3205
Mailing Address 3090 NOWITZKI WAY SUITE 300 DALLAS TX 75219
Business Address 3090 NOWITZKI WAY SUITE 300 DALLAS TX 75219 833-393-6684
HYPERION DEFI, INC. (Filer) CIK: 0001682639 (see all company filings)

EIN.: 471178401 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38365 | Film No.: 261160872
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)